Introduction
The incidence of esophageal adenocarcinoma (EA) has increased 300-400% in western countries over the past four decades (1) . It is widely accepted that EA develops on a background of Barrett's esophagus, a metaplastic columnar-lined epithelium that replaces the normal squamous cell epithelium of the distal esophagus (2) . Progression of Barrett's esophagus into invasive EA is reflected histologically by the metaplasia-dysplasia-carcinoma sequence (3, 4) . Although smoking, Barrett's esophagus, obesity and gastroesophageal reflux disease (GERD) are identified as risk factors for EA, only a fraction of individuals with these risk factors develop EA, which suggests that both genetic factors and lifestyle risk factors may modulate individual susceptibility to EA risk.
Angiogenesis is a process in which endothelial cells divide and migrate to form new capillaries that support the continuous growth of tumor through blood flow (5) . There is increasing evidence that angiogenesis is an essential process in cancer development and metastasis (6) . Also, angiogenesis has been associated with the metaplasia-dysplasia-carcinoma sequence of Barrett's carcinoma (7, 8) . Vascular endothelial growth factor (VEGF) is a critical angiogenic factor, and inhibition of VEGF has been correlated with suppression of tumor growth and angiogenesis (9) (10) (11) (12) (13) . Excessive VEGF expression and VEGF-induced angiogenesis have been involved in the precancerous lesions of esophagus and EA (14) (15) (16) (17) (18) , suggesting that VEGF-driven angiogenesis might be an early event in EA carcinogenesis. Functional genetic polymorphisms at positions À460C/T, þ405C/G and þ936C/T in the VEGF gene have been correlated to VEGF promoter activity, gene expression, protein production (19) (20) (21) and risks of other cancers (22) (23) (24) (25) (26) . The aims of the present study were to investigate whether these functional VEGF polymorphisms are associated with increased risk of EA and whether the associations between VEGF polymorphisms and EA risk are modulated by smoking or other risk factors.
Materials and methods

Study population
This study was approved by the Human Subjects Committees of Massachusetts General Hospital, Dana Farber Cancer Institute and the Harvard School of Public Health (Boston, MA). All participants provided informed, written consent. Incident patients with histologically confirmed EA were recruited prospectively at Massachusetts General Hospital between 1999 and 2005 and at Dana Farber Cancer Institute between 2004 and 2005. All cases were .18 years of age and were diagnosed within 6 months prior to study entry. All patients had tumors that were deemed endoscopically or at the time of resection to have a tumor center located at or above the gastroesophageal junction (midpoint of length located at or above the gastroesophageal junction) and to have at least two-thirds of the bulk tumor located in the esophagus. The controls were comprised of healthy non-blood-related family members (usually spouses) and friends of other thoracic cancer/surgical patients who were visiting patients, also over the age of 18 years. Controls who reported a previous diagnosis of any cancer (except non-melanoma skin cancer) were excluded from participation. For both cases and controls, interviewer-administered questionnaires collected information on age, gender, race, body mass index, smoking status (non-, ex-and current smokers) and pack-years of smoking. Smoking habits were defined at 1 year prior to diagnosis for cases or 1 year prior to interview for controls. Non-smokers smoked ,100 cigarettes in their lifetime. Questions on GERD symptoms in controls were added midway through recruitment. Chronic GERD was defined as having reflux, heartburn or regurgitation symptoms at least once a month for at least a 6 month continuous period in one's lifetime.
Genotyping assays
Genome DNA was extracted from peripheral blood samples using the Puregene DNA Isolation Kit (Gentra Systems/Qiagen, Valencia, CA) following the manufacturer's protocol. The allelic discrimination of the VEGF gene was assessed using Taqman and minor groove binder assays. The primers and probes for the À460C/T (rs833061) and À405C/G (rs2010963) were ordered from Applied Biosystems (Foster city, CA) and the þ936C/T (rs3025039) from Nanogen (Bothell, WA). The wild-type genotype probes were FAM labeled and the variant genotype probes were VIC labeled. Genotyping was performed by laboratory personnel blinded to subject status, and a random 10% of the samples were repeated to validate genotyping procedures. Two authors reviewed independently all genotyping results.
Statistical analysis
We restricted the analysis to Caucasians, because Caucasians composed .90% of our study population. Demographic characteristics between cases and controls were compared using the chi-square, Fisher exact and Student's t-test, where appropriate. Hardy-Weinberg disequilibrium of the VEGF polymorphisms was checked in controls. Detection of linkage disequilibrium among the three polymorphisms was based on Lewontin's D# in controls. Haplotypes of the three VEGF polymorphisms were generated using the SAS macro HAPPY program (27) . Missing variables were analyzed using the Multiple Imputation process.
Genotype and haplotype associations with EA risk were analyzed using unconditional logistic regression models. Logistic regression models were fit to examine the relationship between the log odds of EA and each polymorphism, after adjusting for possible confounding factors such as age, gender, smoking status, pack-years of smoking, years since smoking cessation (if exsmoker), body mass index at age 18 and GERD. Firstly, we investigated the associations between individual VEGF polymorphisms and the risk of EA in separate logistic regression models. Secondly, we estimated gene-environment interactions using genotype-smoking interaction models. Lastly, we investigated the associations between VEGF haplotypes and the risk of EA, treating expected haplotype scores as observed covariates in a standard unconditional logistic analysis, instead of assigning each subject with the most likely haplotype pair. All statistical analyses were undertaken using the SAS statistical packages (SAS version 9.1 Institute, Cary, NC).
Results
Population characteristics
Basic demographic characteristics for cases and controls are summarized in Table I . All cases and controls were Caucasians. Participation rates for both cases and controls exceeded 85%. Mean ages were not significantly different for cases and controls. There were more males in cases than in controls. Body mass index at 18 years old in cases was significantly higher than that in controls (P 5 0.003). Not surprisingly, more smokers, higher smoking pack-years and higher GERD prevalence were seen in the cases, as these are known risk factors for the development of EA (P , 0.0001).
Associations between VEGF genotypes and EA risk Each of the VEGF polymorphisms in the controls was consistent with Hardy-Weinberg equilibrium (P . 0.05, chi-squared goodness of fit). Genotype frequencies of the À460C/T, þ405C/G and þ936C/T polymorphisms in controls were in close agreement with those previously published for healthy Caucasian individuals (28, 29) . Table II shows VEGF genotype distributions between EA cases and controls. There were no statistically significant overall differences between cases and controls for the distributions of À460C/T, þ405C/G and þ936C/T polymorphisms. When the combined variant genotypes were compared with the corresponding wild-type genotypes, the þ936CTþTT and the þ405CGþCC genotypes in cases were significantly differed between cases and controls (Table II) .
There were no overall associations between individual À460C/T genotypes and the risk of EA. However, in non-smokers, the À460CT [adjusted odds ratio (OR) 5 0.36; 95% confidence interval (CI), 0.18-0.73; P 5 0.005] and the À460CTþCC genotypes were significantly associated with lower risk of developing EA (adjusted OR 5 0.49; 95% CI, 0.25-0.91; P 5 0.025). In contrast, the À460CT (adjusted OR 5 1.59; 95% CI, 1.06-2.38; P 5 0.025) and the À460CTþCC (adjusted OR 5 1.57; 95% CI, 1.07-2.30; P 5 0.021) were associated with higher risk of EA in smokers (Table III) . We then evaluated a genotype-smoking interaction model using non-smokers with the wild-type genotypes as reference groups. We observed a gene-smoking interaction between the À460C/T polymorphism and smoking status (non-smoker versus ever-smoker). The adjusted OR for gene-smoking interactions was 3.32 (95% CI, 1.56-7.10; interaction P 5 0.002), (Table IV) . To further quantify genesmoking interaction, we calculated ORs for interaction based on different smoking pack-year categories. We observed that the ORs of À460C/T-pack-year interaction were consistently correlated to the pack-year levels in a dose-response manner (Figure 1) .
For the þ936C/T polymorphism, the adjusted OR of the variant þ936CTþTT genotype versus the wild-type þ936CC was 1.49; 95% CI, 1.05-2.12; P 5 0.027 (Table III) . No significant interaction was detected between the þ936C/T polymorphism and smoking in the risk of EA. No significant association was found between the þ405C/G polymorphism and EA risk.
Association between VEGF haplotypes and EA risk There were six common haplotypes (.2%) among both cases and controls. The distribution of different haplotypes was similar between cases and controls (Table II) and were comparable with previous reports in Caucasians (28, 29) . The most common haplotype was the À460C/þ405G/þ936C (CGC), with the frequencies of 41% in cases and 42% in controls. In overall analysis, haplotype frequencies in cases were significantly different from that in controls (P 5 0.022). 
VEGF-smoking interaction and esophageal adenocarcinoma risk
In haplotype association analysis where the most common haplotype CGC was treated as reference group, the CGT haplotype was significantly associated with higher risk of EA development (adjusted OR 5 1.70; 95% CI, 1.05-2.69; P 5 0.032; global test P , 0.0001). No interactions between any haplotypes and smoking status were found in stratified analyses.
Discussion
VEGF-induced angiogenesis is an early event of EA development. Polymorphisms that can alter VEGF expression and protein production may contribute to the risk of EA. We tested this hypothesis by evaluating the relationship between three functional polymorphisms of VEGF gene and the risk of EA. We found that the þ936C/T polymorphism and specific VEGF haplotypes were significantly associated with higher risk of EA. In addition, we found a significant interaction between smoking and À460C/T polymorphism and a greater risk of developing EA. The þ936C/T polymorphism has been studied in relation to various cancers with disparate results. It has been reported to be associated with decreased risk of breast cancer and small cell lung cancer (22, 24) , but another lung cancer study found no relationship (29) . In separate studies, this polymorphism has been studied in several cancers with mixed results (28, (30) (31) (32) . We know of no previous studies investigating the role of þ936C/T polymorphism in EA risk. In the present study, we found that the variant T allele of the þ936C/T polymorphism was significantly associated with increased risk of EA. Consistent with this result, haplotype CGT that contains the þ936T allele showed a similar association with the risk of EA. The observed þ936CTþTT-EA associations in our study were consistent with reports of the function of þ936CTþTT in other cancers that are characterized histologically by adenocarcinomas, such as colorectal, breast and gastric cancers (30, 31, 33) .
The strong interaction effects of the À460C/T polymorphism and smoking suggest that this polymorphism is not an independent risk factor, but probably an effect modifier that acts synergistically with smoking on EA risk. Previous studies that explored the relationship between VEGF À460C/T genotypes and cancer risk found inconsistent results. The À460C/T polymorphism was found to be associated with prostate cancer risk (34), but no associations were observed in malignant melanoma, lung and renal cell cancers (29, 35, 36) . The reasons for these discrepancies are not completely understood, but if the effect of this polymorphism is only through an interaction with smoking, then main effects may not be observed depending on the distribution of smoking variables across cases and controls. Further, the relevant interactions with smoking may be different as the magnitudes of relationship between cigarette smoking and various cancer risks are different.
Mechanisms for the interaction between smoking and the À460C/T polymorphism could be at the level of gene expression or protein activity through angiogenesis pathways (37, 38) . The À460C/T polymorphisms have been associated with variation in VEGF expression and protein production (20, 21) . Smoking can stimulate both angiogenesis and VEGF expression, which exacerbates the procarcinogenic effect of angiogenesis (37) (38) (39) (40) . Additionally, it has been shown that smoke-induced VEGF expression and release were mediated by other pathways, such as the epidermal growth factor receptor-extracellular signal-regulated kinase, 5-lipoxygenase, oxidative stress, inflammatory responses and beta-adrenoceptors pathways (38, 39, 41, 42) . It is possible that cigarette smoke and VEGF activate multiple effects on EA carcinogenesis.
We found no overall association of þ405C/G or its interaction with smoking on EA risk. There are conflicting reports in the literature on the exact function of the þ405G/C polymorphism. The variant C allele of the þ405G/C polymorphism has been associated with lower VEGF production, and the presence of a C allele may disrupt the myeloid zinc finger 1 transcription factor-binding site (20) . However, some groups reported that higher VEGF level or no association with the þ405C/C genotype (43) (44) (45) . Any association between þ405C/G and EA may be through its linkage disequilibrium with À460C/T and þ936C/T.
We recognize several limitations to our study. Firstly, we only evaluated three functional polymorphisms of the VEGF gene. Whether other genetic variants in the VEGF gene would also be associated with EA risk requires further investigation. Secondly, although we adjusted for various confounding variables in our analysis, diet, environmental and occupational exposure data were not included in our logistic regression models because of incomplete or missing information. However, given the consistent results of individual genotypes, gene-environment interaction effects and haplotype analysis, these potential confounders would probably not substantially change the results. Thirdly, the significant associations between VEGF polymorphisms and EA risk were observed in only one study population. These findings should be validated in independent studies, as well as expanded to cover more completely the entire angiogenic pathway. Finally, multiple comparisons may have led to spuriously significant results. Even if we corrected the level of significance for the number of main and gene-smoking interaction analyses (12 in total) using the Bonferroni method, the interaction between À460C/T and smoking status would still be significant. In summary, this is the first report to our knowledge of the associations between VEGF genotypes, haplotypes and gene-smoking interaction with the risk of EA. Our findings emphasize the importance of considering joint effects of genetic polymorphisms and environmental factors when investigating the risks of EA carcinogenesis. Confirmatory studies and in vitro functional assays are needed to confirm the results and identify the mechanisms underlining the associations. 
